Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Live attenuated influenza vaccine
 Nurse administering the FluMist product | |
| Vaccine description | |
|---|---|
| Target | Influenza |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | Flumist, Flumist Quadrivalent, Fluenz Tetra |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intranasal |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
  (what is this?) (verify) | |
Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that is recommended for the prevention of influenza.[2][7]
It is an attenuated live vaccine, unlike other influenza vaccines, which are inactivated vaccines. Live attenuated influenza vaccine is administered intranasally,[8] while inactivated vaccines are administered by intramuscular injection. Live attenuated influenza vaccine is sold under the brand names FluMist and FluMist Quadrivalent in the United States; and the brand name Fluenz Tetra in the European Union.[4][6] FluMist was first introduced in 2003 by MedImmune.[9][10][11]
In the United States, FluMist is approved for self- or caregiver-administration.[12][13] It is the first influenza vaccine that does not need to be administered by a health care provider.[12]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ a b "Flumist- influenza vaccine live intranasal spray". DailyMed. 6 August 2024. Retrieved 21 September 2024.
- ^ Cite error: The named reference
FDA Flumistwas invoked but never defined (see the help page). - ^ a b "FluMist Quadrivalent". U.S. Food and Drug Administration (FDA). 15 November 2019. STN 125020. Archived from the original on 28 November 2019. Retrieved 28 November 2019.
- ^ Cite error: The named reference
Fluenz EPARwas invoked but never defined (see the help page). - ^ a b "Fluenz Tetra EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 28 November 2019. Retrieved 27 November 2019.
- ^ Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE (September 2008). "Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age". Vaccine. 26 (38): 4940–4946. doi:10.1016/j.vaccine.2008.07.013. PMID 18662737.
- ^ Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. (CAIV-T Comparative Efficacy Study Group) (February 2007). "Live attenuated versus inactivated influenza vaccine in infants and young children". The New England Journal of Medicine. 356 (7): 685–696. doi:10.1056/NEJMoa065368. PMID 17301299.
- ^ "FDA Information Regarding FluMist Quadrivalent Vaccine". U.S. Food and Drug Administration (FDA). 16 January 2018. Archived from the original on 28 November 2019. Retrieved 27 November 2019.
- ^ Midthun K, Masiello S (17 July 2003). "CBER Approval Letter, Influenza Virus Vaccine, Live, Intranasal (FluMist)". U.S. Food and Drug Administration (FDA). Archived from the original on 29 September 2007. Retrieved 6 July 2008.
- ^ "FluMist". U.S. Food and Drug Administration (FDA). Archived from the original on 22 July 2017. Retrieved 10 April 2020.
- ^ a b "FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration". U.S. Food and Drug Administration. 20 September 2024. Retrieved 21 September 2024.
This article incorporates text from this source, which is in the public domain.
- ^ Jewett C (20 September 2024). "Nasal Flu Vaccine Is Approved for At-Home Use". The New York Times. Retrieved 24 September 2024.
Previous Page Next Page
